Pet imaging with [68Ga]NOTA-RGD for prostate cancer: A comparative study with [18F]fluorodeoxyglucose and [18F]fluoroethylcholine

Current Cancer Drug Targets

Volumn 14, Issue 4, 2014, Pages 371-379

  Israel, Ina ^a   Richter, Dominik ^a   Stritzker, Jochen ^a   van Ooschot, Michaela ^a   Donat, Ulrike ^a   Buck, Andreas K ^a   Samnick, Samuel ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Angiogenesis; PET imaging; Prostate cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUOROETHYLCHOLINE F 18; GALLIUM 68; GALLIUM 68 NOTA RGD; UNCLASSIFIED DRUG; 68GA-1,4,7-TRIAZACYCLONONANE-1,4-7-TRIACETIC ACID-ISOTHIOCYANATOBENZYL-C(ARG-GLY-ASP-TYR-LYS); AFFINITY LABELING; BETA3 INTEGRIN; CD51 ANTIGEN; CHOLINE; COORDINATION COMPOUND; CYCLO(ARGINYL-GLYCYL-ASPARTYL-PHENYLALANYL-VALYL); CYCLOPEPTIDE; FLUOROETHYLCHOLINE; GALLIUM; INTEGRIN; OLIGOPEPTIDE; RADIOPHARMACEUTICAL AGENT; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RADIOACTIVITY; TUMOR XENOGRAFT; AFFINITY LABELING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CHEMISTRY; COMPARATIVE STUDY; DIAGNOSTIC USE; DRUG EFFECTS; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATE; PROSTATE TUMOR; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

AFFINITY LABELS; ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CHOLINE; COORDINATION COMPLEXES; FLUORODEOXYGLUCOSE F18; GALLIUM RADIOISOTOPES; HUMANS; INTEGRIN ALPHAV; INTEGRIN BETA3; INTEGRINS; ISOTOPE LABELING; MALE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; PEPTIDES, CYCLIC; POSITRON-EMISSION TOMOGRAPHY; PROSTATE; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 84903738051     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666140403123452     Document Type: Article

References (34)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics 2013. CA Cancer J. Clin. 2013, 63, 11-30.
2. Crawford, E. D.; Stone, E. Y.; Koo, P. J.; Freedland, S. J.; Slovin, S. F.; Gomella, L. G.; Berger, E. R.; Keane, T. E.; Sieber, P.; Shore, N. D.; Petrylak, D. J.; Prostate Cancer RADAR Group. Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology 2014, 83(3), 664-669.
3. Ceci, F.; Castellucci, P.; Mamede, M.; Schiavina, R.; Rubello, D.; Fuccio, C.; Ambrosini, V.; Boschi, S.; Martorana, G.; Fanti, S. 11CCholine PET/CT in hormonal resistant patients showing biochemical relapse after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging 2013, 40(2), 149-155.
4. Iremashvili, V.; Manoharan, M.; Lokeshwar, S. D.; Rosenberg, D. L.; Pan, D.; Soloway, M. S. Comprehensive analysis of postdiagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients. BJU. Int. 2013, 111(3), 396-403.
5. Vickers, A. J.; Thompson, I. M.; Klein, E.; Carroll, P. R.; Scardino, P. T. A. Commentary on PSA velocity and doubling time for clinical decisions in prostate cancer. Urology 2014, 83(3), 592-598.
6. Fox, J. J.; Schöder, H.; Larson, S. M. Molecular imaging of prostate cancer. Curr. Opin. Urol. 2012, 22, 320-327.
7. Tombal, B.; Lecouvet, F. Modern detection of prostate cancer's bone metastasis: Is the bone scan era over? Adv. Urol. 2012, 2012, 893193.
8. Durmus, T.; Baur, A.; Hamm, B. Multiparametric Magnetic Resonance Imaging in the Detection of Prostate Cancer. Rofo 2014, 186(3), 238-246.
9. Kuru, T. H.; Roethke, M. C.; Seidenader, J.; Simpfendörfer, T.; Boxler, S.; Alammar, K.; Rieker, P.; Popeneciu, V. I.; Roth, W.; Pahernik, S.; Schlemmer, H. P.; Hohenfellner, M.; Hadaschik, B. A. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer. J. Urol. 2013, 190(4), 1380-1386.
10. Heidenreich, A.; Bastian, P. J.; Bellmunt, J.; Bolla, M.; Joniau, S.; Mason, M. D.; Matveev, V.; Mottet, N.; van der Kwast, T. H.; Wiegel, T.; Zattoni, F. The updated EAU guidelines on prostate cancer. European Association of Urology. 2013, www.uroweb.org/guidelines/online-guidelines/ (Accessed March 22, 2014).
11. Evangelista, L.; Zattoni, F.; Guttilla, A.; Saladini, G.; Zattoni, F.; Colletti, P. M.; Rubello, D. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin. Nucl. Med. 2013, 38(5), 305-314.
12. Fuccio, C.; Castellucci, P.; Schiavina, R.; Guidalotti, P. L.; Gavaruzzi, G.; Montini, G. C.; Nanni, C.; Marzola, M. C.; Rubello, D.; Fanti, S. Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. Eur. J. Radiol. 2012, 81(8), e893-e896.
13. 18F]-choline PET/CT for staging and restaging of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2008, 35(2), 253-263.
14. Hodolic, M.; Michaud, L.; Huchet, V.; Balogova, S.; Nataf, V.; Kerrou, K.; Vereb, M.; Fettich, J.; Talbot, J. N. Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer: a dual centre survey. Radiol Oncol. 2014, 48(1), 20-28.
15. Rybalov, M.; Breeuwsma, A. J.; Leliveld, A. M.; Pruim, J.; Dierckx, R. A.; de Jong, I. J. Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer. World J Urol. 2013, 31(2), 319-323.
16. Giovacchini, G.; Picchio, M.; Scattoni, V.; Garcia Parra, R.; Briganti, A.; Gianolli, L.; Montorsi, F.; Messa, C. PSA doubling time for prediction of [11C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging 2010, 37(6), 1106-1116.
17. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 2005, 438, 932-936.
18. Hood, J. D.; Cheresh, D. A. Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2002, 2(2), 91-100.
19. Nicholson, B.; Theodorescu, D. Angiogenesis and prostate cancer tumor growth. J. Cell. Biochem. 2004, 91(1), 125-150.
20. 3 and endothelial ICAM-1 by simvastatin inhibits prostate cancer micrometastasis. J. Cell. Physiol. 2013, 228(11), 2139-2148.
21. Zheng, D.; Woodard, A. S.; Fornaro, M.; Tallini, G.; Languino, L. R. Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res. 1999, 59(7), 1655-1664.
22. Cai, W.; Niu, G.; Chen, X. Imaging of integrins as biomarkers for tumor angiogenesis. Curr. Pharm. Des. 2008, 14(28), 2943-2973.
23. 3 integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug. ACS Nano. 2012, 6(5), 4530-4539.
24. 3 expression. Theranostics 2011, 1, 48-57.
25. 68Gaand 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur. J. Nucl. Med. Mol. Imaging 2008, 35(8), 1507-1515.
26. 18F-labeled RGD dimer peptide with PEG (4) linkers. Eur. J. Nucl. Med. Mol. Imaging 2009, 36(8), 1296-1307.
27. Ferl, G. Z.; Dumont, R. A.; Hildebrandt, I. J.; Armijo, A.; Haubner, R.; Reischl, G.; Su, H.; Weber, W. A.; Huang, S. C. Derivation of a compartmental model for quantifying 64Cu-DOTA-RGD kinetics in tumor-bearing mice. J. Nucl. Med. 2009, 50(2), 250-258.
28. 68Ga-labeled RGD conjugates show improved PET imaging of ανβ3 integrin expression and facile radiosynthesis. J. Nucl. Med. 2011, 52(8), 1276-1284.
29. 68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug. Chem. 2011, 22(12), 2415-2422.
30. Samnick, S.; Nestle, U.; Wagner, M.; Schaefer, A.; Menger, M. D.; Kirsch, C. M. Validation of 8-[123I]iodo-L-1,2,3,4-tetrahydro-7- hydroxyisoquinoline-3-carboxylic acid as an imaging agent for prostate cancer in experimental models of human prostatic cancer. Nucl. Med. Mol. 2007, 34(1), 99-107.
31. 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7- triacetic acid and feasibility studies in mice. J. Nucl. Med. 2008, 49(5), 830-836.
32. 68Ga-1,4,7-Triazacyclononane-1,4-7-triacetic acidisothiocyanatobenzyl- c(Arg-Gly-Asp-d-Tyr-Lys). Molecular Imaging and Contrast Agent Database (MICAD). Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. 2011, www.ncbi.nlm.nih.gov/books/NBK53807/ (Accessed March 22, 2014).
33. 3 integrin expression. Eur. J. Nucl. Med. Mol. Imaging 2011, 38(7), 1303-1312.
34. 18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J. Urol. 2002, 168(1), 273-280.